Medical Genetics Center

What Medical Genetics Center does

MGZ - Medizinisch Genetisches Zentrum is an owner-operated medical genetics practice and accredited laboratory headquartered in Munich, Germany, with 17 branch locations across Bavaria, Baden-Württemberg, and North Rhine-Westphalia. The center employs 219 staff as of Q1 2026 and operates as an integrated clinical and diagnostic operation, providing physician-led genetic counseling combined with in-house molecular and cytogenetic laboratory services. Core diagnostic offerings include exome sequencing, whole genome sequencing, SNP microarray analysis, NGS-based gene panels, non-invasive prenatal testing (NIPT Trisomie and NIPT Monogen), liquid biopsy for cancer detection and monitoring, and a state-licensed preimplantation genetic diagnosis center (PID-Zentrum München) designated by the Bavarian government.

The technology stack spans conventional cytogenetics through cutting-edge NGS, methylation analysis, and duplex-sequencing-based liquid biopsy, with specialized partnerships providing access to externally-developed analytical pipelines: Baylor Genetics (NIPT Monogen), TruDiagnostic (epigenetic aging clocks), and Allelica (breast cancer polygenic risk scores). Beyond clinical diagnostics, MGZ operates a preventive genetics portfolio including the proprietary praeCon-Test® (600+ gene carrier screening), PreCan® (70-gene tumor prevention panel), PreCardio (30+ gene cardiovascular panel), polygenic risk scores across nine common disease areas, pharmacogenetic testing for 22 genes/113 variants, and epigenetic aging clocks (OMICmAge, DunedinPace, SYMPHONY Age). Variant classification follows ACMG guidelines enhanced by ENIGMA Expert Panel specifications, with active research output including a 2025 Editor's Choice publication in Genetics in Medicine Open on BRCA1/BRCA2 variant reclassification.

The business model blends two revenue streams: (1) statutory and private health insurance reimbursement for clinically-indicated genetic counseling and diagnostics, and (2) out-of-pocket self-pay (IGeL) preventive services priced between €247 and €1,990. Distribution combines physician-to-physician referral networks, direct patient appointments bookable via Doctolib at all 17 locations, hospital-embedded branches within oncological and pediatric centers, and a home self-test channel for preventive genetics. The center is led by Managing Director Prof. Dr. Elke Holinski-Feder and operates without external investment or parent company ownership.

Name

Medical Genetics Center

Legal name

MGZ - Medizinisch Genetisches Zentrum

Website

https://mgz-muenchen.de

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

MGZ - Medizinisch Genetisches Zentrum is an owner-operated Munich-based medical genetics practice and accredited laboratory offering physician-led genetic counseling, in-house molecular and cytogenetic diagnostics, and preventive genetics services to patients and referring physicians across 17 German locations.

Ownership category

akta.pro rank

Product category

Medical Genetics Diagnostic Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Pharmacogenomics (PGx) Decision Support (HLAAANAB), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Genetic diagnostic services
• Medical genetics laboratory
• Prenatal genetic testing
• Cancer genetic testing
• Preventive genetic screening

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices16 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Public and Private Health Insurance Billing: Genetic counseling and indicated genetic diagnostics are covered by both public (gesetzliche) and private (private) health insurers in Germany. Patients can attend consultations with their insurance card or a referral.
2. Preventive / Self-Pay Services (IGeL): Preventive genetic tests not covered by statutory health insurance are offered as individual health services (IGeL-Leistungen). Patients pay out-of-pocket for services such as polygenic risk scores, aging clocks, pharmacogenetics, and comprehensive risk screening packages.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Medical Genetics Center (MGZ) is an owner-operated practice and laboratory for human genetics in Munich offering physician-led genetic counseling paired with in-house DAkkS-accredited diagnostic testing. Its core services include cytogenetic and molecular genetic diagnostics, NGS-based exome and genome sequencing, non-invasive prenatal testing (NIPT), liquid biopsy for cancer, and preventive genetics panels covering hereditary cancer, cardiovascular, carrier screening, polygenic risk scores, pharmacogenetics, and epigenetic aging clocks.

Product overview

The MGZ – Medizinisch Genetisches Zentrum is an owner-operated practice and laboratory for human genetics offering a comprehensive, integrated portfolio of genetic counseling and diagnostic services. The core offering consists of physician-led genetic counseling sessions combined with an in-house accredited laboratory providing cytogenetic and molecular genetic testing. Key diagnostic products include exome and genome sequencing, SNP microarray, and NGS-based multi-gene panels across all medical specialties. Specialized offerings include Non-Invasive Prenatal Tests (NIPT Trisomie and NIPT Monogen), Liquid Biopsy for cancer detection and monitoring, and Carrier Screening via the praeCon-Test® brand. In preventive genetics, MGZ offers polygenic risk scores (PRS) for cardiovascular disease and breast cancer, pharmacogenetic testing (PGx-Standard and PerforM), and Aging Clock/epigenetic signature analyses. The portfolio also includes disease-specific panels such as Tumor-Präventions-Panel PreCan® (70 genes) and Präventionspanel PreCardio (>30 genes). Specialized centers include the ZET – Zentrum für Erbliche Tumorerkrankungen (hereditary cancer) and PID-Zentrum München (preimplantation diagnosis). Analysis services are complemented by online appointment booking via Doctolib and secure data transfer via FTAPI.

Differentiator

Problem solved

Functional benefit

Brands

• NIPT: Prenatal testing for aneuploidies, CNV, RhD, and monogenic disorders
• praeCon-Test®
• ZET – Zentrum für erbliche Tumorerkrankungen
• PID-Zentrum München
• PRS Mammakarzinom
• PRS Cardio
• PreCan®
• PreCardio

Products and services

• Genetic Counseling

Quantifiable outcome

• 12,374 samples processed and 6,339 exome-based analyses conducted in Q1 2026 alone, demonstrating high-volume diagnostic capacity.

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature8 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• PID-Zentrum MünchencoreStrategic or Co-development PartnerMGZ is a state-licensed PID (preimplantation genetic diagnosis) center designated by the Bavarian government. Offers PID using NGS and SNP microarray-based analysis on trophectoderm and polar bodies for couples with hereditary genetic disease risk. Located at the same Munich facility.
• ZET – Zentrum für Erbliche TumorerkrankungencoreStrategic or Co-development PartnerMGZ-founded center for hereditary cancer diseases providing comprehensive care including genetic counseling, diagnostics, predictive testing, and risk-adapted screening recommendations. Serves as a public information forum and specialist support hub for hereditary cancer syndromes.
• ERN GENTURIS (European Reference Network for Rare Tumour Syndromes)coreStrategic or Co-development PartnerMGZ participates in ERN GENTURIS, a European reference network for patients with rare genetic tumor risk syndromes, contributing to cross-border healthcare collaboration.
• GHGA (German Human Genome-Phenome Archive)minorStrategic or Co-development PartnerMGZ is associated with GHGA, contributing to and benefiting from Germany's national genome-phenome data infrastructure for research purposes.
• NASGE (Nationale Aktionsgemeinschaft zur Aufklärung über Seltene Erkrankungen)minorStrategic or Co-development PartnerMGZ participates in NASGE, the National Action Community for Information on Rare Diseases, supporting public awareness and education efforts.
• Praxisnetz HumangenetikminorChannel Partner/ Reseller/ DistributorMGZ is a member of the Practice Network Human Genetics (Praxisnetz Humangenetik), facilitating referral relationships and collaborative care with other human genetics practices.
• Baylor Genetics (Houston, Texas, USA)coreTechnology or IntegrationMGZ partners with Baylor Genetics for the NIPT Monogen test, which is performed at Baylor Genetics' facility. Medical validation of results is conducted by MGZ physicians. Samples are pseudonymized before transmission.
• VemaH-Study / Deutsches Herzzentrum BerlinminorStrategic or Co-development PartnerMGZ cooperates with the VemaH study (Versorgungssituation Erwachsener mit angeborenen Herzfehlern) led by TU Dresden and the German Heart Center Berlin, investigating care for adults with congenital heart defects.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Allelica: Polygenic risk score analytics company and MGZ technology partner for breast cancer PRS; emerging competitor and enabler in the consumer-facing PRS market across Europe.
• GeneDx (a Sema4 company): US-based clinical genomics lab specializing in rare disease exome/genome sequencing and hereditary cancer panels with growing international presence; comparable to MGZ's high-complexity exome diagnostics offering.

Direct peers

• Centogene: Germany-based (Rostock) rare disease and genetic diagnostics laboratory offering NGS-based panels, exome/genome sequencing, NIPT, and hereditary cancer testing directly comparable to MGZ's core diagnostics portfolio.
• University Hospital Genetics Departments (e.g., Institut für Humangenetik, TU München / LMU München): Academic genetics institutes at German university hospitals provide exome, genome, and hereditary disease diagnostics and compete directly with MGZ for physician referrals and complex case work in Bavaria.

Broad incumbents

• Eurofins Genomics: Division of Eurofins Scientific offering a broad portfolio of genomic services including Sanger sequencing, NGS, microarrays, and genetic testing across Europe — competing on scale and price for many of MGZ's routine molecular diagnostics services.
• SYNLAB Group: Pan-European medical diagnostics network with broad laboratory offerings; operates human genetics services and competes with MGZ in routine diagnostic testing and physician-referred genetic panels across Germany.
• LGC Biosearch Technologies / LGC Clinical Diagnostics: Genomics-focused life sciences company providing molecular and genetic testing services and reference laboratory capacity across Europe, including reproductive and hereditary disease testing.

Others

• Baylor Genetics: Houston-based genetic testing laboratory and MGZ's strategic partner for NIPT Monogen; operates comparable NIPT, exome and rare disease diagnostics — represents both collaboration and indirect competitive threat in Germany.
• TruDiagnostic: US-based epigenetic clock and biological age testing laboratory that supplies MGZ's aging clock analytics; a competitor in the broader longevity diagnostics market and a key technology partner for MGZ.

Regional players

• MVZ Humangenetik (regional German genetics practices): Network of regional German human genetics practices (e.g., Humangenetik Wuppertal) offering genetic counseling and routine diagnostics; competes with MGZ in their respective local catchment areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MGZ_Germany

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medical Genetics Center